Try a new search

Format these results:

Searched for:

All

Total Results:

532344


Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort

Erlandson, Kristine M; Geng, Linda N; Selvaggi, Caitlin A; Thaweethai, Tanayott; Chen, Peter; Erdmann, Nathan B; Goldman, Jason D; Henrich, Timothy J; Hornig, Mady; Karlson, Elizabeth W; Katz, Stuart D; Kim, C; Cribbs, Sushma K; Laiyemo, Adeyinka O; Letts, Rebecca; Lin, Janet Y; Marathe, Jai; Parthasarathy, Sairam; Patterson, Thomas F; Taylor, Brittany D; Duffy, Elizabeth R; Haack, Monika; Julg, Boris; Maranga, Gabrielle; Hernandez, Carla; Singer, Nora G; Han, Jenny; Pemu, Priscilla; Brim, Hassan; Ashktorab, Hassan; Charney, Alexander W; Wisnivesky, Juan; Lin, Jenny J; Chu, Helen Y; Go, Minjoung; Singh, Upinder; Levitan, Emily B; Goepfert, Paul A; Nikolich, Janko Ž; Hsu, Harvey; Peluso, Michael J; Kelly, J Daniel; Okumura, Megumi J; Flaherman, Valerie J; Quigley, John G; Krishnan, Jerry A; Scholand, Mary Beth; Hess, Rachel; Metz, Torri D; Costantine, Maged M; Rouse, Dwight J; Taylor, Barbara S; Goldberg, Mark P; Marshall, Gailen D; Wood, Jeremy; Warren, David; Horwitz, Leora; Foulkes, Andrea S; McComsey, Grace A; ,
BACKGROUND/UNASSIGNED:There are currently no validated clinical biomarkers of postacute sequelae of SARS-CoV-2 infection (PASC). OBJECTIVE/UNASSIGNED:To investigate clinical laboratory markers of SARS-CoV-2 and PASC. DESIGN/UNASSIGNED:Propensity score-weighted linear regression models were fitted to evaluate differences in mean laboratory measures by prior infection and PASC index (≥12 vs. 0). (ClinicalTrials.gov: NCT05172024). SETTING/UNASSIGNED:83 enrolling sites. PARTICIPANTS/UNASSIGNED:RECOVER-Adult cohort participants with or without SARS-CoV-2 infection with a study visit and laboratory measures 6 months after the index date (or at enrollment if >6 months after the index date). Participants were excluded if the 6-month visit occurred within 30 days of reinfection. MEASUREMENTS/UNASSIGNED:Participants completed questionnaires and standard clinical laboratory tests. RESULTS/UNASSIGNED:levels was attenuated after participants with preexisting diabetes were excluded. Among participants with prior infection, no meaningful differences in mean laboratory values were found between those with a PASC index of 12 or higher and those with a PASC index of zero. LIMITATION/UNASSIGNED:Whether differences in laboratory markers represent consequences of or risk factors for SARS-CoV-2 infection could not be determined. CONCLUSION/UNASSIGNED:Overall, no evidence was found that any of the 25 routine clinical laboratory values assessed in this study could serve as a clinically useful biomarker of PASC. PRIMARY FUNDING SOURCE/UNASSIGNED:National Institutes of Health.
PMCID:11408082
PMID: 39133923
ISSN: 1539-3704
CID: 5711402

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review

Leiva, Orly; Liu, Olivia; Zhou, Sophia; How, Joan; Lee, Michelle; Hobbs, Gabriela
Myeloproliferative neoplasms (MPN) are a heterogenous group of disorders of clonal hematopoiesis characterized by constitutive activation of the JAK/STAT signaling pathway leading to proliferation of blood cells. Cardiovascular disease (CVD) contributes significantly to the morbidity and mortality of patients with MPN. Particularly well-known CVD complications of MPNs are arterial and venous thrombotic events. However, MPNs are also associated with other forms of CVD including atrial fibrillation, heart failure, and pulmonary hypertension. Recent studies have characterized outcomes of patients with MPN and CVD, including acute myocardial infarction (AMI), heart failure, atrial fibrillation, and pulmonary hypertension. Additionally, optimal cardiovascular disease prevention strategies in patients with MPN are not yet clear. Further investigation is warranted to improve CVD outcomes in patients with MPN. Clinicians should be aware of cardiovascular complications of MPN, including thrombotic as well as non-thrombotic complications (heart failure, arrhythmias, pulmonary hypertension).
PMID: 39278999
ISSN: 1534-6277
CID: 5711442

Habit and Help-Experiences of Technology Use During the COVID-19 Pandemic: Interview Study Among Older Adults

Kilaberia, Tina R; Hu, Yuanyuan; Bell, Janice F
BACKGROUND:The COVID-19 pandemic compelled older adults to engage with technology to a greater extent given emergent public health observance and home-sheltering restrictions in the United States. This study examined subjective experiences of technology use among older adults as a result of unforeseen and widespread public health guidance catalyzing their use of technology differently, more often, or in new ways. OBJECTIVE:This study aimed to explore whether older adults scoring higher on the Unified Theory of Acceptance and Use of Technology questionnaire fared better in aspects of technology use, and reported better subjective experiences, in comparison with those scoring lower. METHODS:A qualitative study using prevalence and thematic analyses of data from 18 older adults (mean age 79 years) in 2 groups: 9 scoring higher and 9 scoring lower on the Unified Theory of Acceptance and Use of Technology questionnaire. RESULTS:Older adults were fairly competent technology users across both higher- and lower-scoring groups. The higher-scoring group noted greater use of technology in terms of telehealth and getting groceries and household items. Cognitive difficulty was described only among the lower-scoring group; they used technology less to get groceries and household items and to obtain health information. Qualitative themes depict the role of habit in technology use, enthusiasm about technology buttressed by the protective role of technology, challenges in technology use, and getting help regardless of technology mastery. CONCLUSIONS:Whereas the pandemic compelled older adults to alter or increase technology use, it did not change their global outlook on technology use. Older adults' prepandemic habits of technology use and available help influenced the degree to which they made use of technology during the COVID-19 pandemic.
PMID: 39422990
ISSN: 2561-326x
CID: 5711242

Genetic sex validation for sample tracking in next-generation sequencing clinical testing

Hu, Jianhong; Korchina, Viktoriya; Zouk, Hana; Harden, Maegan V; Murdock, David; Macbeth, Alyssa; Harrison, Steven M; Lennon, Niall; Kovar, Christie; Balasubramanian, Adithya; Zhang, Lan; Chandanavelli, Gauthami; Pasham, Divya; Rowley, Robb; Wiley, Ken; Smith, Maureen E; Gordon, Adam; Jarvik, Gail P; Sleiman, Patrick; Kelly, Melissa A; Bland, Harris T; Murugan, Mullai; Venner, Eric; Boerwinkle, Eric; ,; Prows, Cynthia; Mahanta, Lisa; Rehm, Heidi L; Gibbs, Richard A; Muzny, Donna M
OBJECTIVE:Data from DNA genotyping via a 96-SNP panel in a study of 25,015 clinical samples were utilized for quality control and tracking of sample identity in a clinical sequencing network. The study aimed to demonstrate the value of both the precise SNP tracking and the utility of the panel for predicting the sex-by-genotype of the participants, to identify possible sample mix-ups. RESULTS:Precise SNP tracking showed no sample swap errors within the clinical testing laboratories. In contrast, when comparing predicted sex-by-genotype to the provided sex on the test requisition, we identified 110 inconsistencies from 25,015 clinical samples (0.44%), that had occurred during sample collection or accessioning. The genetic sex predictions were confirmed using additional SNP sites in the sequencing data or high-density genotyping arrays. It was determined that discrepancies resulted from clerical errors (49.09%), samples from transgender participants (3.64%) and stem cell or bone marrow transplant patients (7.27%) along with undetermined sample mix-ups (40%) for which sample swaps occurred prior to arrival at genome centers, however the exact cause of the events at the sampling sites resulting in the mix-ups were not able to be determined.
PMID: 38433186
ISSN: 1756-0500
CID: 5710682

Professor Alessandro Zuddas' Impact and Legacy: The Influential Networking and Human Connection Skills of a Passionate Scientist, Clinical Academic, and Pioneer in Child and Adolescent Psychopharmacology

Carucci, Sara; Di Martino, Adriana; Castellanos, Francisco Xavier; Masi, Gabriele; Banaschewski, Tobias; Coghill, David; Moreno, Carmen; Cortese, Samuele
Professor Alessandro Zuddas, from the University of Cagliari (Italy), passed away prematurely in July 2022. As a prominent figure in child and adolescent neuropsychiatry, he substantially influenced the fields of neurodevelopmental disorders and neuropsychopharmacology both nationally and internationally. Professor Zuddas was a renowned expert in basic and clinical research in child and adolescent psychopharmacology, an enlightened and stimulating educator, and a mentor to many students, residents, and senior colleagues. With his enthusiasm and unique ability to network, he contributed enormously to trace a path in the field that we continue to follow. His name will remain in the textbooks and articles he authored. Here, as colleagues and friends who had the honor to work with him, we provide our personal views of Alessandro's impact and legacy, which go far beyond his publications.
PMID: 39403746
ISSN: 1557-8992
CID: 5711042

Machine learning, deep learning and hernia surgery. Are we pushing the limits of abdominal core health? A qualitative systematic review

Lima, D L; Kasakewitch, J; Nguyen, D Q; Nogueira, R; Cavazzola, L T; Heniford, B T; Malcher, F
INTRODUCTION:This systematic review aims to evaluate the use of machine learning and artificial intelligence in hernia surgery. METHODS:The PRISMA guidelines were followed throughout this systematic review. The ROBINS-I and Rob 2 tools were used to perform qualitative assessment of all studies included in this review. Recommendations were then summarized for the following pre-defined key items: protocol, research question, search strategy, study eligibility, data extraction, study design, risk of bias, publication bias, and statistical analysis. RESULTS:A total of 13 articles were ultimately included for this review, describing the use of machine learning and deep learning for hernia surgery. All studies were published from 2020 to 2023. Articles varied regarding the population studied, type of machine learning or Deep Learning Model (DLM) used, and hernia type. Of the thirteen included studies, all included either inguinal, ventral, or incisional hernias. Four studies evaluated recognition of surgical steps during inguinal hernia repair videos. Two studies predicted outcomes using image-based DMLs. Seven studies developed and validated deep learning algorithms to predict outcomes and identify factors associated with postoperative complications. CONCLUSION:The use of ML for abdominal wall reconstruction has been shown to be a promising tool for predicting outcomes and identifying factors that could lead to postoperative complications.
PMID: 38761300
ISSN: 1248-9204
CID: 5711322

A gain-of-function variant in SREBF1 causes generalized skin hyperpigmentation with congenital cataracts [Case Report]

Wang, Huijun; Wu, Yuan; Bassetti, Jennifer A; Wang, Zhaoyang; Oza, Vikash S; Rangu, Sneha A; McGivern, Bobbi; Peng, Sha; Liang, Lina; Huang, Shimiao; Gong, Zhuoqing; Xu, Zigang; Lin, Zhimiao
BACKGROUND:Lipid metabolism has essential roles in skin barrier formation and the regulation of skin inflammation. Lipid homeostasis regulates skin melanogenesis, although the underlying mechanism remains largely unknown. Sterol regulatory element binding protein 1 (SREBP-1) is a key transcription factor essential for cellular lipid metabolism. Loss-of-function variants in SREBF1 are responsible for autosomal-dominant ichthyosis follicularis, alopecia and photophobia syndrome, emphasizing the significance of lipid homeostasis in skin keratinization. OBJECTIVES/OBJECTIVE:To identify the genetic basis of a new entity featuring diffuse skin hyperpigmentation with congenital cataracts, and to unravel the underlying mechanism for the pathogenesis of the SREBF1 variant. METHODS:Whole-exome sequencing was performed to identify underlying genetic variants. Quantitative polymerase chain reaction, Western blot and immunofluorescence staining were used to assess the expression and the subcellular localization of the SREBF1 variant. The transcriptional activity of mutant SREBP-1 was determined by a luciferase reporter assay. A transgenic zebrafish model was constructed. RESULTS:Two unrelated patients presented with generalized skin hyperpigmentation with skin xerosis, congenital cataracts and extracutaneous symptoms. We identified a de novo nonsense variant c.1289C>A (p.Ser430*) in SREBF1 in both patients. The variant encoded a truncated protein that showed preferential nucleus localization, in contrast to wild-type SREBP-1 which - in sterol-sufficient conditions - is mainly localized in the cytoplasm. The luciferase reporter assay revealed that the p.Ser430* mutant exhibited enhanced transcriptional activity. Cultured patient primary melanocytes showed increased melanin synthesis vs. those from healthy controls. At 35 days postfertilization, the p.Ser430* transgenic zebrafish model exhibited more black spots, along with upregulated expression of melanogenic genes. CONCLUSIONS:We demonstrated that a gain-of-function variant of SREBF1 causes a previously undescribed disorder characterized by generalized skin hyperpigmentation and congenital cataracts. Our study reveals the involvement of SREBP-1 in melanogenesis and lens development, and paves the way for the development of novel therapeutic targets for skin dyspigmentation or cataracts.
PMID: 39005171
ISSN: 1365-2133
CID: 5711362

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

Le Pen, Jérémie; Paniccia, Gabrielle; Kinast, Volker; Moncada-Velez, Marcela; Ashbrook, Alison W; Bauer, Michael; Hoffmann, H-Heinrich; Pinharanda, Ana; Ricardo-Lax, Inna; Stenzel, Ansgar F; Rosado-Olivieri, Edwin A; Dinnon, Kenneth H; Doyle, William C; Freije, Catherine A; Hong, Seon-Hui; Lee, Danyel; Lewy, Tyler; Luna, Joseph M; Peace, Avery; Schmidt, Carltin; Schneider, William M; Winkler, Roni; Yip, Elaine Z; Larson, Chloe; McGinn, Timothy; Menezes, Miriam-Rose; Ramos-Espiritu, Lavoisier; Banerjee, Priyam; Poirier, John T; Sànchez-Rivera, Francisco J; Cobat, Aurélie; Zhang, Qian; Casanova, Jean-Laurent; Carroll, Thomas S; Glickman, J Fraser; Michailidis, Eleftherios; Razooky, Brandon; MacDonald, Margaret R; Rice, Charles M
Interferons (IFNs) play a crucial role in the regulation and evolution of host-virus interactions. Here, we conducted a genome-wide arrayed CRISPR knockout screen in the presence and absence of IFN to identify human genes that influence Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. We then performed an integrated analysis of genes interacting with SARS-CoV-2, drawing from a selection of 67 large-scale studies, including our own. We identified 28 genes of high relevance in both human genetic studies of Coronavirus Disease 2019 (COVID-19) patients and functional genetic screens in cell culture, with many related to the IFN pathway. Among these was the IFN-stimulated gene PLSCR1. PLSCR1 did not require IFN induction to restrict SARS-CoV-2 and did not contribute to IFN signaling. Instead, PLSCR1 specifically restricted spike-mediated SARS-CoV-2 entry. The PLSCR1-mediated restriction was alleviated by TMPRSS2 overexpression, suggesting that PLSCR1 primarily restricts the endocytic entry route. In addition, recent SARS-CoV-2 variants have adapted to circumvent the PLSCR1 barrier via currently undetermined mechanisms. Finally, we investigate the functional effects of PLSCR1 variants present in humans and discuss an association between PLSCR1 and severe COVID-19 reported recently.
PMCID:11486371
PMID: 39316623
ISSN: 1545-7885
CID: 5711472

PAR2 on oral cancer cells and nociceptors contributes to oral cancer pain that can be relieved by nanoparticle-encapsulated AZ3451

Bhansali, Divya; Tu, Nguyen H; Inoue, Kenji; Teng, Shavonne; Li, Tianyu; Tran, Hung D; Kim, Dong H; Dong, Jessy; Peach, Chloe J; Sokrat, Badr; Jensen, Dane D; Dolan, John C; Yamano, Seiichi; Robinson, Valeria Mezzano; Bunnett, Nigel W; Albertson, Donna G; Leong, Kam W; Schmidt, Brian L
Oral cancer is notoriously painful. Activation of protease-activated receptor 2 (PAR2, encoded by F2RL1) by proteases in the cancer microenvironment is implicated in oral cancer pain. PAR2 is a G protein-coupled receptor (GPCR) expressed on neurons and cells in the cancer microenvironment. Sustained signaling of PAR2 from endosomes of neurons mediates sensitization and nociception. We focused on the differential contribution of PAR2 on oral cancer cells and neurons to oral cancer pain and whether encapsulation of a PAR2 inhibitor, AZ3451 in nanoparticles (NP) more effectively reverses PAR2 activation. We report that F2RL1 was overexpressed in human oral cancers and cancer cell lines. Deletion of F2RL1 on cancer cells reduced cancer-associated mechanical allodynia. A third-generation polyamidoamine dendrimer, functionalized with cholesterol was self-assembled into NPs encapsulating AZ3451. NP encapsulated AZ3451 (PAMAM-Chol-AZ NPs) more effectively reversed activation of PAR2 at the plasma membrane and early endosomes than free drug. The PAMAM-Chol-AZ NPs showed greater efficacy in reversing nociception than free drug, with respect to both level and duration, in three preclinical mouse models of oral cancer pain. The antinociceptive efficacy was confirmed with an operant orofacial assay. Genetic deletion of F2RL1 on cancer cells or F2rl1 on neurons each partially reversed mechanical cancer allodynia. The remaining nociception could be effectively reversed by PAMAM-Chol-AZ NPs. These findings suggest that PAR2 on oral cancer cells and neurons contribute to oral cancer nociception and NPs loaded with a PAR2 antagonist provide increased antinociception and improved oral function compared to free drug.
PMID: 39418848
ISSN: 1878-5905
CID: 5711082

Ayahuasca Treatment Outcome Project (ATOP): One-Year Results from Takiwasi Center and Implications for Psychedelic Science

Rush, Brian; Marcus, Olivia; García, Sara; Loizaga-Velder, Anja; Spitalier, Ariane; Mendive, Fernando
OBJECTIVE:This article focuses on the outcomes at 1 year post-treatment of a naturalistic evaluation of services provided through the Takiwasi Centre, an accredited Peruvian therapeutic community offering an ayahuasca-assisted, integrative treatment program for addiction rehabilitation. METHOD/METHODS:= 52) completed structured interviews and a battery of validated instruments. Outcome measures included the Addiction Severity Index (Version 5), the Beck Anxiety and Depression Inventories, the World Health Organization Quality of Life Brief Version (WHOQOL-BREF), and the World Health Organization Quality of Life Spiritual Religious and Personal Belief (WHOQOL-SRPB) scale. Likert rating scales were used to assess perceived importance and significance of different aspects of the program and overall participant satisfaction. RESULTS:The group change from baseline to the 1-year follow-up was significant and in the anticipated direction for alcohol and drug use severity, depression and anxiety, and some dimensions of quality of life. There was considerable individual variation in outcomes and treatment duration. The majority of participants rated all aspects of the program as important, including the spiritual and therapeutic significance of the ayahuasca experience, which was rated as very significant. CONCLUSIONS:Based on the positive 1-year outcomes, and within the limitations of an uncontrolled observational study design, the findings suggest promise for the effectiveness of the use of ayahuasca in a multifactorial treatment context for individuals with significant treatment histories, high levels of comorbidity, and treatment motivation. Results highlight considerable variation in individual experience that merit in-depth qualitative analysis. Implications for ayahuasca-assisted and other psychedelic-assisted treatment alternatives are discussed.
PMID: 37615330
ISSN: 1938-4114
CID: 5711192